DOC

Business profile & competitive position

Healthpeak Properties, Inc. (DOC) is an S&P 500, self-administered UPREIT in the Real Estate / REIT – Healthcare Facilities space. Through its operating subsidiary, Healthpeak OP, the company owns, operates, and develops U.S. real estate tied to healthcare discovery and delivery. As of December 31, 2025, its portfolio held interests in 689 properties split among outpatient medical buildings, lab and life-science buildings, senior housing communities, and a handful of non-reportable investments.

The operating footprint is concentrated in three cash-flow segments. Outpatient medical led the way with 507 properties and 2025 segment Adjusted NOI of $795.8 million. Lab properties contributed $567.4 million across 145 buildings, while senior housing contributed $176.7 million across 34 communities. Those dollar weights matter: outpatient medical and lab together dominate the income stream, so Healthpeak’s competitive profile is less “pure senior-housing landlord” and more “healthcare delivery + life-science real estate platform.”

What do the returns say about the moat? The company’s net margin is 8.6% and its return on equity is 3.3%. Those figures do not point to a wide-moat, high-return business in the classic sense; real estate is capital intensive and REITs routinely carry large asset bases that compress percentage returns. The more meaningful moat arguments show up in the lease and location metrics. Outpatient medical buildings were roughly 79% on or adjacent to hospital campuses, about 96% affiliated with hospital systems, and about 72% triple-net leased by leased square feet. Lab properties were about 89% triple-net leased and heavily concentrated in San Francisco, Boston, and San Diego. Triple-net structures push operating-cost risk to tenants, while hospital-campus adjacency and top-tier life-science clusters make relocation expensive for tenants. Scale, lease structure, and sticky locations—not outsized returns—are the core of the competitive argument.

Financial posture

Healthpeak currently commands a $14.4 billion market cap, trades at a P/E of 59.5, posts an 8.6% net margin, and generates a 3.3% ROE. Its beta is 0.99, implying price volatility roughly in line with the broader market. The valuation multiple is the number that jumps off the page: a P/E near 60 is unusually elevated for a real estate business and reflects either the market’s expectation of meaningful earnings recovery, the premium ascribed to its lab/life-science exposure, or both.

Interpreting that multiple alongside the profitability metrics is important. A 3.3% ROE means the company is not currently earning a high return on the equity base, while a 59.5x P/E means investors are paying a steep price for each dollar of trailing earnings. For a REIT, conventional equity multiples can also be distorted by non-cash depreciation, recurring capital expenditures, and the preference many REIT investors have for funds-from-operations (FFO) or net-asset-value metrics. Even so, the gap between the headline P/E and the thin margin/ROE profile is the central tension in the financial posture: the market is pricing in better days than the current returns imply.

The beta of 0.99 tells traders that DOC is not a defensive, low-volatility hiding place compared with the S&P 500. It will move with the market cycle more than a traditional perception of “bond-proxy” REITs might suggest. Debt structure also matters here; the company emphasizes long-term fixed-rate obligations with staggered maturities, which is relevant because interest-rate risk is one of the largest variables for any leveraged real estate vehicle.

Strategic priorities & outlook

Healthpeak’s most recent 10-K frames four operational priorities. The first is to own, operate, and develop high-quality outpatient medical, lab, and senior housing real estate while managing the portfolio for long-term risk-adjusted returns and dividend growth. That objective lines up with the segment NOI breakdown: outpatient and lab are the engines, while senior housing is the smaller, more specialized piece.

The second priority is balance-sheet strength. The company aims to maintain an investment-grade balance sheet with ample liquidity and primarily long-term fixed-rate debt with staggered maturities, explicitly designed to limit interest-rate and refinancing risk. That language is significant for a capital-intensive REIT, because rollover risk can punish the sector when rates rise or credit markets tighten.

The third priority is internal growth through tenant relationships: working with tenants on space and capital needs, replacing tenants at favorable terms, extending or modifying leases before expiration, and delivering property-management quality that encourages renewals, expansions, and relocations. With roughly 96% of outpatient medical square feet affiliated with hospital systems, tenant retention and rent recapture are critical to protecting that NOI base.

The fourth—and most specific near-term priority—is the proposed Janus Living IPO in the first half of 2026, under which Healthpeak would contribute its 34-community senior housing portfolio, retain a substantial majority ownership interest, and serve as external manager. That transaction would crystallize a standalone value for the senior housing platform while leaving Healthpeak with continued economics and fee income. In January 2026, the company also acquired the remaining 46.5% interest in its SWF SH JV, bringing ownership of those 19 senior housing properties to 100%—a move that prepares the portfolio for the contemplated spin.

Macro & geopolitical exposure

Because Healthpeak is classified as a REIT – Healthcare Facilities company, its exposures follow from that industry definition rather than from firm-specific issues. The most direct macro variable is interest rates. REITs use debt extensively, so the level of Treasury yields, credit spreads, and refinancing conditions affects both borrowing costs and the cap rates investors apply to real estate cash flows. Healthpeak’s preference for long-term fixed-rate debt is a direct response to this exposure.

Healthcare regulation and reimbursement policy are also relevant. Hospital systems and senior housing operators depend on Medicare, Medicaid, and commercial insurance reimbursement. Any legislative or administrative change that squeezes tenant revenues can eventually flow back to landlords through lower rent growth, higher concessions, or elevated default risk. Lab and life-science tenants add a different wrinkle: they are tied to biotech and pharmaceutical R&D spending, which is cyclical and sensitive to capital-market conditions and federal research budgets.

Geographic concentration is another macro consideration. Lab properties were 59% in San Francisco, 22% in Boston, and 17% in San Diego by square feet. Those are high-barrier, high-demand life-science markets, but they also concentrate exposure to regional economic cycles, state-level regulation, construction costs, and local rental dynamics. Outpatient buildings tied to hospital campuses are more geographically diversified, yet they still depend on the financial health of the underlying health systems. Supply-chain disruptions, labor-cost inflation in healthcare, and currency effects are secondary for a domestically focused healthcare REIT, but property-level operating-cost inflation is not.

Recent developments

The latest news flow has been dominated by institutional activity rather than operational headlines. On August 28, 2026, Zacks published “DOC vs. EGP: Which Stock Is the Better Value Option?”—a comparative valuation piece that flags Healthpeak in a peer context. One day earlier, on August 27, 2026, defenseworld.net reported that Adelante Capital Management LLC bought 1,009,623 shares of Healthpeak. That is a meaningful accumulation from a dedicated real-estate investment manager.

On August 21, 2026, two additional filings crossed the tape. Defenseworld.net reported that Advisors Capital Management LLC purchased 75,700 shares, and separately that BlackRock Inc. held a $1.52 billion stake in the company. None of these headlines amount to a forward-looking operational catalyst on their own. Collectively, however, they illustrate that institutional capital continues to flow into the name around the $20–$21 price area and that large asset managers are maintaining or increasing exposure. For traders, the message is one of sponsorship rather than direction confirmation: institutions are active, but their activity does not guarantee near-term price performance.

Earnings behavior & post-earnings drift

Healthpeak’s recent earnings record is a useful reminder that headline results and price action do not always align. Over the last eight reported quarters, DOC has beaten estimates 4 times for a 50% beat rate, with an average earnings surprise of 18.2%. The average 5-day price move after earnings across those quarters is +2.24%, classified as an upward drift. Yet the notable—and more instructive—pattern is that even on beat quarters, the post-earnings drift has not reliably continued in the direction of the surprise.

The last four reports illustrate the inconsistency clearly.

• 2026-08-04: Actual EPS of $0.08 vs. estimate $0.02815 delivered a 184.2% positive surprise. The stock rose 0.79% the next day but then fell 5.13% over the following five sessions.
• 2026-05-05: Actual EPS of $0.28 vs. estimate $0.05276 produced a 430.7% positive surprise. The stock surged 18.11% the next day and extended that gain to +19.81% over five days.
• 2026-02-02: Actual EPS of $0.16 vs. estimate $0.45 was a 64.4% miss. The stock dropped 2.78% the next day but recovered most of it, closing the five-day window down only 0.47%.
• 2025-10-23: Actual EPS of -$0.17 vs. estimate $0.06 registered a 383.3% negative surprise. The stock actually gained 1.19% the next day before selling off 5.23% over the next five sessions.

The takeaway is that DOC earnings days can be noisy. A large beat produced a modest next-day gain followed by a slide; another large beat produced a multi-day rally; a severe miss produced a positive next-day move followed by a slide. The average surprise is positive, and the average five-day drift is up, but the path is volatile and inconsistent. The next scheduled report is October 22, 2026, after the close, with the consensus EPS estimate at $0.05625. As of the latest snapshot, the stock is trading near $20.815, with an RSI of 42.8 and the 50-day EMA at $21.07; price is hovering just under that short-term moving average heading into the report.

For a deeper dive into how analysts, institutional holders, and quantitative models are currently evaluating DOC ahead of the October 22 report, explore the full institutional verdict on the ticker page.